Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Wee-Joo Chng,Sagar Lonial,Gareth J Morgan,Shinsuke Iida,Philippe Moreau,Shaji Kumar,Philip Twumasi-Ankrah,Arun Kumar,Ajeeta B Dash,Alexander Vorog,Xiaoquan Zhang,Kaveri Suryanarayan,Richard Labotka,Meletios A Dimopoulos,S Vincent Rajkumar

doi:10.1182/blood-2021-147838

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Wee-Joo Chng, Sagar Lonial + Show 13 more

Open Access

https://doi.org/10.1182/blood-2021-147838

Copy DOI

Journal: Blood

Publication Date: Nov 5, 2021

Affiliation: Takeda (United States), National and Kapodistrian University of Athens, Nagoya City University, Mayo Clinic, New York University Langone Medical Center, National University Cancer Institute, Singapore, Emory University

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Full Text